A record of what Ajit Mishra said publicly, with the source. Not advice.
“Recommends buying Aurobindo Pharma for the next one to two weeks with a target price of ₹1,320 and a stop loss of ₹1,168. The stock shows notable resilience within the pharma sector, sustaining momentum after breaking out of a broader base and forming a buying pivot near the 20-day EMA.”
Ajit Mishra’s track record (trackable calls only): 135 graded calls · 95% CI 23–39%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹1,320, stop ₹1,168, as stated.
Window: 14 days, the time frame the call states ("one to two weeks").
The stop ₹1,168 was reached on a close before the target ₹1,320. Miss.
The grader’s working: R4 TARGET_CALL: entered ₹1177.4 on 2025-12-08 (next trading session's close); stop ₹1168 breached at close ₹1163.6 on 2025-12-09. Window 14 days — rule H1: the quote states "one to two weeks".
How it played out
How this is worked out- Target or stop first
- The stop was reached on a close before the target was.
- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 1.17% against the call up to 9 Dec 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.